Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies-Reference-Cited by-同舟云学术

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies

Published:2016-06-03 Issue:1 Volume:158 Page:1-9
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Hida Akira I.,Sagara Yasuaki,Yotsumoto Daisuke,Kanemitsu Shuichi,Kawano Junko,Baba Shinichi,Rai Yoshiaki,Oshiro Yumi,Aogi Kenjiro,Sagara Yoshiaki,Ohi Yasuyo

Funder

Division of Clinical Research Promotion at the National Hospital Organization Shikoku Cancer Center

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-016-3848-2.pdf

Reference20 articles.

1. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thurlimann B, Senn HJ, Panel M (2015) Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26(8):1533–1546. doi: 10.1093/annonc/mdv221

2. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW (2011) The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 105(1):93–103. doi: 10.1038/bjc.2011.189

3. Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33(17):1974–1982. doi: 10.1200/JCO.2014.59.4358